Has results × Multiple Myeloma × fludarabine × Clear all
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
35 enrolled 14 charts
NCT00719888 2025-03-07

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Fred Hutchinson Cancer Center

Phase 2 Completed
135 enrolled 19 charts
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT00741455 2020-11-23

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Dartmouth-Hitchcock Medical Center

Phase NA Completed
18 enrolled 7 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT02145039 2019-12-26

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
2 enrolled 11 charts
NCT01499147 2018-11-08

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

University of Illinois at Chicago

Phase NA Completed
100 enrolled 10 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00809276 2015-02-16

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
92 enrolled 5 charts
NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts